Market research
TORC resTORbio, Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 12M
- P/E ratio
- Not available
- Analyst target
- 3
- Dividend yield
- 0.0%
- Beta
- 2.43
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US0070021086
- Market cap
- 12M
- P/E ratio
- Not available
- Analyst target
- 3
- Dividend yield
- 0.0%
- Beta
- 2.43
About
About resTORbio, Inc
resTORbio, Inc., a clinical-stage biopharmaceutical company, develops medicine to treat aging-related diseases. Its lead program is selectively inhibits the target of rapamycin complex 1 (TORC1), an evolutionary conserved pathway that contributes to the age-related decline in function of various organ systems, including immune, neurologic, and cardiac functions. The company's lead drug candidate is RTB101, an oral, selective, and potent inhibitor of TORC1 that is in Phase 1b/2a clinical trial for the treatment of Parkinson's disease, as well as to treat neurodegenerative diseases. resTORbio, Inc. has collaboration with TrialSpark to investigate RTB-101 for COVID-19 on the Project Covalence platform. resTORbio, Inc. was founded in 2016 and is headquartered in Boston, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the TORC discussion.
5 years, 4 months ago
resTORbio, Inc is currently in a long term uptrend where the price is trading 641.5% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
resTORbio, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 77.1% to $-6M since the same quarter in the previous year.
Finally, its free cash flow grew by 75.5% to $-5M since the same quarter in the previous year.
Based on the above factors, resTORbio, Inc gets an overall score of 4/5.